Allergan's Alphagan (brimonidine), for the treatment of open-angleglaucoma and ocular hypertension, is now approved in the UK. The drug is a selective alpha2 agonist which improves intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.
This is the third approval of the product, after the USA, where it has now been launched, and Brazil. Alphagan was recently granted a further indication in the USA and Brazil, for the prevention of postoperative IOP elevations after argon laser trabeculoplasty. Allergan will now seek approval in the rest of the European Union through the mutual recognition process.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze